CHARLOTTE , N.C.--(BUSINESS WIRE)--After much anticipation the FDA has finally approved for market in the United States the Sonablate® for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence which are typically reported with surgery and radiation.
HIFU Prostate Services, LLC (HPS) is a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). Newly appointed HPS Medical Director Michael J. Lazar, MD is set to provide medical guidance and proctoring to new physicians who will now be trained on the Sonacare® HIFU system in surgery centers around the country. Dr. Lazar has been treating patients with HIFU since 2007 and is one of only three U.S. physicians who worked with SonaCare Medical, LLC to supervise HIFU treatments during FDA clinical trials.
John W. Linn, chief executive officer of HPS commented, “I have known Dr. Lazar since 2007 and have been impressed with his patient care and dedication to the HIFU technology since his first treatment. He is the ideal medical director for HPS and for teaching this new technology to US physicians.”
Lazar will also operate his own HIFU Program in partnership with HPS, offering prostate treatments in downtown San Francisco near Union Square at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility that is convenient to hotels and the airport for patients interested in traveling from around the country for HIFU treatments. The actual Sonablate device has just been delivered to the Surgery Center in San Francisco, marking the first time ever that a HIFU device will be available at a medical center in the United States.
“It is very exciting to be a part of providing the vehicle for access to this technology for new and experienced HIFU users. Over the years, physicians in various stages of training have shown remarkable enthusiasm for providing HIFU for their prostate cancer patients, but they did not see a clear path for obtaining accessibility to the technology after FDA approval,” said Lazar. “HIFU Prostate Services takes the mystery and tedium out of the process by providing the highest quality of care, support and technology to the patient and to the urology community. Men who choose HIFU can contact HPS and then be referred to a regional HIFU surgeon. This approach facilitates wide availability of this treatment option for American men.”
HIFU offers patients a single, outpatient treatment for prostate cancer that is bloodless and allows men to return to their normal lifestyles within a few days. Although HIFU is designed as a single treatment, it can be repeated if needed. HIFU may also be used to treat patients that have failed radiation therapy and it does not preclude any future treatments including surgery or radiation.
About HIFU Prostate Services, LLC & Dr. Michael Lazar
At HIFU Prostate Services (HPS), our mission is to partner with physicians to deliver the highest quality of care, support and technology to the patient and to the urology community for the treatment of localized prostate cancer using high intensity focused ultrasound (HIFU). HPS was founded in 2015 by a seasoned management team with over 50 years of experience in the healthcare industry and over 30 years focused on HIFU technologies. The company is headquartered in Charlotte, N.C.
Dr. Michael Lazar has been certified by the American Board of Urology four times and has practiced in Santa Rosa, California since 1983. He is chairman of the Board of Redwood Health Services, Inc. providing insurance products for employee groups. Lazar is also CEO and managing director of Santa Rosa Surgical Management Company, LLC that manages the ambulatory surgery center at Santa Rosa Memorial Hospital. Lazar received his urology training at Louisiana State University in New Orleans, La. and is a graduate of University of Arkansas Medical School.